Figures computed from official regulatory filings — .
Statistical track record
Free accountWin rates, median returns and the proven-insider analysis come with a free account.
Create a free accountThis page republishes public regulatory disclosures.
| Company | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
Armata Pharmaceuticals, Inc.Listing on record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC | ||
Armata Pharmaceuticals, Inc.Listing on record | Buy | $26.9M | conv 47 | SEC | |
Entasis Therapeutics Holdings Inc.Listing unverified | BuyD (derivative) | $7.5M | SEC | ||
Entasis Therapeutics Holdings Inc.Listing unverified | Buy | $7.5M | conv 13 | SEC | |
Armata Pharmaceuticals, Inc.Listing on record | Buy | $13.9M | conv 43 | SEC | |
Armata Pharmaceuticals, Inc.Listing on record | BuyD (derivative) | $13.9M | SEC | ||
Entasis Therapeutics Holdings Inc.Listing unverified | Buy | $12.5M | conv 23Unusual size | SEC | |
Entasis Therapeutics Holdings Inc.Listing unverified | BuyD (derivative) | $12.5M | Unusual size | SEC | |
Entasis Therapeutics Holdings Inc.Listing unverified | BuyD (derivative) | $31.7M | SEC | ||
Entasis Therapeutics Holdings Inc.Listing unverified | Buy | $31.7M | conv 59 | SEC | |
Armata Pharmaceuticals, Inc.Listing on record | BuyD (derivative) | $22.1M | First in 12mo | SEC | |
Armata Pharmaceuticals, Inc.Listing on record | Buy | $22.1M | conv 68First in 12mo | SEC | |
Theravance Biopharma, Inc.Listing on record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |